FDA Approves First Gene Therapy for Inherited Deafness (npr.org)

• First FDA-authorized gene therapy for genetic auditory loss.
• Corrects OTOF-mediated protein deficiency in the cochlea.
• Shifts the paradigm from mechanical amplification to cellular restoration.

"The FDA has granted approval for the first gene therapy targeting hereditary deafness caused by OTOF gene mutations. By delivering a functional copy of the gene directly to the inner ear, the treatment restores the protein necessary for auditory signals to travel from hair cells to the brain. This medical advancement represents a departure from traditional cochlear implants, moving toward biological restoration. It signifies a significant leap in precision medicine, demonstrating the viability of gene-based interventions for non-life-threatening but life-altering sensory conditions."